Blood Thinner Eliquis Tied to Louisana Woman's DeathJun 13, 2016
A lawsuit has been filed against Bristol-Myers Squibb and Pfizer by the representative of the estate of a woman from Louisiana who died allegedly from the use of Eliquis. The blood thinner Eliquis (apixaban) is an anticoagulant meant to prevent blood clots and strokes, but can have serious side effects including brain bleeding, gastrointestinal bleeding and severe pain, reports Top Class Actions.
In 2012, the U.S. Food and Drug Administration (FDA) approved Eliquis as a blood thinner that may be used in the treatment of atrial fibrillation. Clinical trials known as Aristotle were the basis for the FDA approval which some people called “dubious.”
The Aristotle studies were brought into the Eliquis lawsuit because the defendants allegedly hired incompetent and untrustworthy people in China to perform the studies in an effort to save money. The testing agents are accused of fraud for not reporting a death that occurred during the study, not following up with subjects, making dispensing errors where some subjects never even received the drug, falsifying records and, overall poor quality control, Top Class Actions reports.
One of the benefits the public sees in Eliquis is that it does not have to be rigorously monitored with regular blood tests and strict dietary rules, the way its chief competitor warfarin (Coumadin), requires. Warfarin, however, has an antidote that can be administered to stop excessive bleeding. There is no antidote for Eliquis.
The lack of an antidote for the “new generation” of blood thinners, including Pradaxa and Xarelto, has led to thousands of product liability lawsuits against the manufacturers. The plaintiffs are alleging that these drugs were manufactured and sold and the dangers were not revealed to warn users that a reversal agent was non-existent, according to Top Class Actions.